Drug Profile
OCX 191
Alternative Names: 3-AP; 3-Apct; NSC 663249; NSC#663249; NTO-1151; OCX-0191; OCX-191; TriapineLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Yale University
- Developer National Cancer Institute (USA); National Resilience; Trethera; Vion Pharmaceuticals
- Class Antineoplastics; Pyridines; Small molecules; Thiosemicarbazones
- Mechanism of Action Ribonucleotide reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Gynaecological cancer
- Phase II Cervical cancer; Solid tumours
- No development reported Breast cancer; Cholangiocarcinoma; Gallbladder cancer; Haematological malignancies; Head and neck cancer; Leukaemia; Neuroendocrine tumours; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer
- Discontinued Cancer; Cancer metastases; Hepatitis B; Herpes simplex virus infections; HIV infections
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Neuroendocrine-tumours(Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 02 Jun 2023 Efficacy and adverse events data from the phase III NRG GY006 trial in Gynaecological cancer presented at 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 14 Apr 2023 Safety, efficacy and pharmacokinetics data from phase I trial in Neuroendocrine tumours was presented at 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)